| November 2 |
Alnylam Presents New Pre-Clinical Data on ALN-TTR, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis |
| November 2 |
Avila Presents Data on Its Novel, Orally-Available Protease Inhibitor, AVL-181, Demonstrating Viral Clearance of Hepatitis C Virus in Preclinical Models |
| November 2 |
Salix Pharmaceuticals Reviews American Association for the Study of Liver Diseases Annual Meeting |
| November 2 |
Dynavax's HEPLISAV Shows Increased Protection Rate for Chronic Kidney Disease Patients |
| November 2 |
Results from two Canadian studies confirm sustained viral response rates seen in hepatitis C patients treated with Pegatron |
| November 2 |
Novobiotics - Positive Initial Phase IIa Data |
| November 2 |
GlobeImmune's Hepatitis C Therapeutic Vaccine Combined with Standard of Care Increases End of Treatment Response Rate by 15% |
| November 2 |
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced Melanoma |
| November 2 |
Æterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer |
| November 2 |
Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies |
| November 2 |
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of Benlysta in Systemic Lupus Erythematosus |
| November 2 |
Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting |
| November 2 |
Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints |
| November 2 |
Zosano Pharma, Inc. to Provide Pipeline Updates at the 2009 AAPS Annual Meeting |
| November 2 |
UCL (University College London) Liver Failure Group Present Two Studies on a Novel Treatment Option (OCR-002) for Complications of Hyperammonemia in Liver Failure at the 60th Annual AASLD Meeting |
| November 2 |
Twice Daily Oral Medication Shows Promise in Treating Patients with Hepatitis C |
| November 2 |
YM BioSciences reports positive nimotuzumab four-year survival data presented at ASTRO 2009 |
| November 2 |
Enzo Biochem Reports on Favorable Clinical Trial of EGS21 for Treatment of Non-Alcoholic Steatohepatitis |
| November 2 |
Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating Viread For Chronic Hepatitis B |
| November 2 |
Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C |
| November 2 |
BARACLUDE (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated Cirrhosis |
| November 2 |
FibroGen Announces New Research in Anti-CTGF and HIF-PHI Therapeutic Development Programs in Kidney Disease |
| November 2 |
NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis |
| November 2 |
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C |
| November 2 |
Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder |
| November 3 |
Sanofi Pasteur Presents Safety Data on Menactra Vaccine Given to Infants at Infectious Disease Society Meeting |
| November 3 |
Study Finds Lack of Diffusible VEGF Growth Factor Can Cause Retinal Defects Similar to Dry Macular Degeneration |
| November 3 |
Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009 |
| November 3 |
MagForce Nanotechnologies AG reaches primary study endpoint in pivotal glioblastoma study |
| November 3 |
SCYNEXIS' SCY-635 Demonstrates Positive Antiviral Activity in Combination with Approved and Investigational Anti-HCV Agents |
| November 3 |
ARIAD's AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor |
| November 3 |
Ironwood and Forest Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation |
| November 3 |
INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227 |
| November 3 |
Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference |
| November 4 |
New Phase IIa data on TMC435 in patients with hepatitis C presented at the ongoing AASLD - meeting |
| November 4 |
Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and Predicting Disease Free Survival |
| November 4 |
Promedior Announces Publication of Preclinical Studies in Science Translational Medicine Demonstrating that hSAP Inhibits Kidney Fibrosis |
| November 4 |
Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs Against Chlorine Gas Exposure in Animal Studies |
| November 4 |
New Data on Attention in Children with ADHD |
| November 4 |
Concerta in the Classroom: New Data on Attention in Children With ADHD |
| November 4 |
Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference |
| November 5 |
Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) Meeting |
| November 5 |
Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX (Varenicline) Compared With Placebo |
| November 5 |
Chelation Therapy Drug Found Safe and Beneficial for Children With Autism |
| November 5 |
Short-Term Hormone Therapy Added to Radiation Increases Survival for Medium-Risk, But Not Low-Risk, Prostate Cancer Patients |
| November 5 |
BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology |
| November 5 |
Ocera Therapeutics Presents Clinical Data Demonstrating AST-120 Relieves Pruritus in Patients with Liver Cirrhosis at the 60th Annual AASLD Meeting |
| November 5 |
Amgen Announces Overall Survival Results for Vectibix in First-Line Metastatic Colorectal Cancer |
| November 5 |
Approved Lymphoma Drug Shows Promise in Early Tests Against Bone Cancer |
| November 5 |
M. D. Anderson News Release: Early Stage, HER2 Positive Breast Cancer Patients at Increased Risk of Recurrence |
| November 5 |
New Safety Data on Menactra for Infants |
| November 5 |
Journal Cancer Publishes Pivotal Study of TREANDA in Patients with in Relapsed Indolent NHL |
| November 5 |
New Data on Bendamustine Offers Hope to Non-Hodgkin's Lymphoma Patients Resistant to Standard Therapy |
| November 5 |
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD) Annual Meeting |
| November 6 |
ZIOPHARM Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data at Annual Meeting of the Connective Tissue Oncology Society |
| November 6 |
Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting |
| November 6 |
Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting |
| November 6 |
NexBio Publishes Two Articles Showing DAS181 (Fludase) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses |
| November 6 |
Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox |
| November 9 |
BrainStorm Stem Cell Therapy Treatment Shown To Be More Effective Than Other Current Potential Stem Cell Treatments |
| November 9 |
ISTA Pharmaceuticals Highlights Bepreve Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) |
| November 9 |
Pandemic 2009 Influenza Update: Pandemrix data on co-administration with annual seasonal influenza vaccine (Fluarix) |
| November 9 |
Æterna Zentaris: Scientific Article Supports Perifosine?s Development in Kidney Cancer |
| November 9 |
Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered with PH20 Enzyme |
| November 9 |
Zosano Pharma, Inc. Announces Publication of Positive Phase 2 Study of Its ZP-PTH Patch for Osteoporosis Therapy |
| November 9 |
DX-88 (ecallantide) Demonstrated Relief of Symptoms in Hereditary Angioedema Acute Attacks in All Attack Locations |
| November 9 |
CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response |
| November 9 |
OssulinTM, a Novel Oral Insulin Product, Shows Promising Bioavailability for Advancing Diabetes Therapy |
| November 9 |
NexBio Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 |
| November 9 |
SuperGen Presentations at AACR-NCI-EORTC |
| November 10 |
ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
| November 10 |
Roche reports positive Phase II results with potential first-in-class treatment for the negative symptoms of schizophrenia |
| November 10 |
Avanir Pharmaceuticals Announces Zenvia Safety and Efficacy Data from Star Trial Open Label Extension |
| November 10 |
Cytos Biotechnology updates on the development of the hypertension vaccine CYT006-AngQb |
| November 10 |
Labopharm's novel trazodone formulation subject of publication in peer-reviewed medical journal |
| November 10 |
Independent Study Utilizing Cyclic Levulan PDT Finds 95 Percent Reduction in New Squamous Cell Carcinoma Lesions in Solid Organ Transplant Recipients Over a 2-Year Period |
| November 11 |
Crinone 8% (progesterone vaginal gel) As Effective as Hormone Injections During IVF? Is Medscape's ?Top News? from The ASRM 65th Annual Meeting |
| November 11 |
More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51st American Society of Hematology Meeting |
| November 11 |
Geron Collaborators Publish Data on hESC-Derived Glial Progenitor Cell Therapy in Cervical Spinal Cord Injury |
| November 11 |
DUSA's Levulan PDT found to reduce squamous cell carcinomas by 95% in solid organ transplant recipients |
| November 11 |
BioClinica to Host Medical Imaging Symposium for Rheumatoid Arthritis Clinical Trials on November 18, 2009 |
| November 11 |
NanoViricides, Inc. to Present Anti-Influenza Drug Candidate FluCide Studies at the Influenza Congress 2009 |
| November 11 |
Avanir Pharmaceuticals Announces Zenvia Safety and Efficacy Data from Star Trial Open Label Extension |
| November 11 |
Drugs to Treat Anemia in Cancer Patients Linked to Thromboembolism |
| November 11 |
Video: Sanofi Pasteur Announces Final Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Adults and Children |
| November 11 |
Viron to Present Data from Phase II Trial at American Heart Association Conference |
| November 11 |
Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda) Combination Therapy Reduces Early Breast Cancer Recurrence |
| November 12 |
Mersana Therapeutics Publishes Review Article Detailing Advantages of its Lead Cancer Compound in Journal of Advanced Drug Delivery Reviews |
| November 12 |
Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII |
| November 12 |
BioAlliance Pharma Presents Results for Its New Oral Chemotherapy Nanoparticle Innovation at the AAPS Annual Meeting in Los Angeles, November 8 to 12, 2009 |
| November 12 |
Holllis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone (HE3235) at Molecular Targets and Cancer Therapeutics Conference |
| November 12 |
Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology |
| November 12 |
Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome |
| November 13 |
BioTime CEO Dr. Michael West to Present at Stem Cells USA & Regenerative Medicine Congress 2009 |
| November 13 |
Cleviprex Results Reported From Study in Patients With Intracerebral Hemorrhage |
| November 16 |
Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer Did Not Meet Primary Endpoint |
| November 16 |
Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable Suspension for the Treatment of Opioid Dependence |
| November 16 |
Genta Announces Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced Melanoma |
| November 16 |
Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial |
| November 16 |
Gentium Announces Presentation of Defibrotide Clinical Data at the American Society of Hematology Annual Meeting |
| November 16 |
BioInvent and ThromboGenics Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients with Advanced Solid Tumours |
| November 17 |
Novartis Influenza A(H1N1) 2009 vaccine US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1) |
| November 17 |
NicOx - NCX 6560 meets primary and secondary objectives in first-in-man study |
| November 17 |
Ticagrelor (BRILINTAT) Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting |
| November 17 |
The Medicines Company Announces Positive Phase III Data in Two Late-Breakers at AHA and in NEJM |
| November 17 |
Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV (guanfacine) Extended-Release Tablets with Stimulants |
| November 17 |
Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA |
| November 17 |
Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting |
| November 17 |
American Heart Association Late Breaking Clinical Trial Report: Treatment for Iron Deficiency Improves Symptoms, Functional Capacity and Quality of Life in Chronic Heart Failure Patients |
| November 17 |
Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results |
| November 17 |
AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting |
| November 17 |
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma |
| November 17 |
Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference |
| November 17 |
Interim Phase 2 Survival Data for PV-10 Will Be Presented by Professor John F. Thompson, MD, on November 21, 2009 |
| November 17 |
Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific Sessions |
| November 17 |
NeoPharm Presents the Phase I Data for Patients with Metastatic Solid Tumors |
| November 17 |
Higher Dose of Merck's Cozaar (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study |
| November 17 |
Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patient to Receive PLX-PAD |
| November 17 |
Aegerion Pharmaceuticals Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile |
| November 17 |
BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction |
| November 17 |
Semafore Pharmaceuticals Announces Phase I Data Presentation Highlighting Novel PI3K Pathway Inhibitor at 51st ASH Annual Meeting |
| November 17 |
American Heart Association Late Breaking Clinical Trial Report: High Dose of Angiotensin Receptor Blockers Effective in Heart Failure Patients |
| November 17 |
YM Biosciences Reports Cyt997 Oral Vascular Disrupting Agent Results Presented At AACR-NCI-EORTC Meeting |
| November 18 |
Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder |
| November 18 |
Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer |
| November 18 |
Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association |
| November 18 |
ImmunoGen Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma |
| November 18 |
Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder |
| November 18 |
Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients |
| November 18 |
Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302 |
| November 18 |
Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction/Positive BPH Results |
| November 18 |
Cardiovascular Outcomes with Ezetimibe and Simvastatin Similar to Statin Alone, Claims Data Suggest |
| November 18 |
Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference |
| November 18 |
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference |
| November 18 |
Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body |
| November 18 |
Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS |
| November 18 |
Synta Presents New Data on Mechanism of Action of Elesclomol at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics |
| November 18 |
Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090 |
| November 19 |
Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTC |
| November 19 |
Medivir: Epiphany Biosciences Announces Positive Results from Its Phase 2b Trial in Shingles |
| November 19 |
Basilea presents new research data on oncology drug candidate BAL27862 at international cancer conference |
| November 19 |
ImmuPharma announces Positive Ph2b Lupuzor trial results |
| November 19 |
Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. |
| November 19 |
VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction; Data Demonstrate Robust Efficacy, Favorable Side-Effect Profile |
| November 19 |
Positive Results from Chronic Study with Bayer ?s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009 |
| November 19 |
Military Study Shows Prevention of Novel A/H1N1 Virus Infection is Vaccine-Type and Age-Dependent |
| November 20 |
Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical Studies |
| November 20 |
Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting |
| November 20 |
Genasense Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma |
